DiagnaMed Congratulates QIMC on Quebec Drill Permit Approval and Announces Significant Progress on Ontario Clean Natural Hydrogen Soil Sampling Program

Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company") proudly congratulates Québec Innovative Materials Corp. (QIMC) on receiving approval of their drill permit from the Government of Quebec. This permit issuance follows rigorous due diligence by provincial authorities and represents a strong endorsement of the innovative clean natural hydrogen model and methodologies developed collaboratively by QIMC and the Institut National de la Recherche Scientifique (INRS).

This significant milestone highlights governmental recognition of the scientific validity and environmental integrity of QIMC and INRS's exploration approach. Notably, the same validated clean natural hydrogen exploration methods are currently being applied by QIMC and INRS on DiagnaMed's properties in Northern Ontario, strategically positioned on the geological continuation of QIMC's St-Bruno-de-Guigues assets.

Diagnamed is also pleased to announce substantial progress in the ongoing clean natural hydrogen soil sampling program being conducted by the QIMC-INRS team on DiagnaMed's Northern Ontario holdings. To date, five of the planned eleven soil sampling lines have been completed, resulting in the collection of over 500 soil samples. This progress underscores the significant potential for clean natural hydrogen and supports the sustainable development of hydrogen assets on both DiagnaMed's and QIMC's properties in Northern Ontario.

DiagnaMed remains committed to advancing innovative and environmentally responsible clean natural hydrogen solutions and looks forward to a continued successful collaboration with QIMC and INRS.

About DiagnaMed Holdings Corp.

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a Canadian technology innovator specializing in advanced hydrogen extraction technologies designed to support the rapidly growing natural hydrogen industry. Focused on commercial scalability, DiagnaMed aims to deliver cost-effective, sustainable, and efficient hydrogen solutions critical for global energy security and decarbonization. Visit DiagnaMed.com.

For more information, please contact:

John Karagiannidis, President and CEO

DiagnaMed Holdings Corp.
Tel: 514-726-7058
Email: info@diagnamed.com
Website: www.diagnamed.com

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "projected", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the Three and Six Months Ended March 31, 2025 ("MD&A"), dated May 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

DiagnaMed
CSE:DMED OTC:DGNMF

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259831